Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB-001 (Vilobelimab) in ANCA-associated Vasculitis
NCT05197842Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Feb 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vilobelimab in granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), sponsored by Staidson Biopharmaceutical. Started Feb 2022; status: completed.
02
Drugs
vilobelimab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT05197842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197842.